Browsing Tag
AIM:FARN
1 post
Is Faron Pharmaceuticals (AIM: FARN) turning a corner? Bexmarilimab shows 85% ORR in HR-MDS as ESMO data boosts confidence
Faron Pharmaceuticals’ updated ESMO 2025 data shows 85% ORR and new biomarker insight for bexmarilimab in HR-MDS. Find out why this trial may redefine the biotech’s future.